FASN and metabolic dysfunction-associated steatotic liver disease: In addition, Gao et al. demonstrated that mitochondrial pyruvate carrier 1 can regulate the Kla of fatty acid synthase and the Kla at the K673 site can suppress fatty acid synthase activity, mediating the downregulation of liver lipid accumulation, which might provide a clue to treatment of nonalcoholic fatty liver disease [103].